Rivastigmine
- Generic Name
- Rivastigmine
- Brand Names
- Exelon, Nimvastid, Prometax, Rivastigmine Sandoz, Rivastigmine 1 A Pharma, Rivastigmine Hexal, Rivastigmine Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C14H22N2O2
- CAS Number
- 123441-03-2
- Unique Ingredient Identifier
- PKI06M3IW0
- Background
Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
- Indication
For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
- Associated Conditions
- Dementia With Lewy Body Disease, Mild Dementia due to Parkinson's disease, Mild Dementia of the Alzheimer's Type, Moderate Alzheimer's Type Dementia, Moderate Dementia due to Parkinson's disease
Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)
Phase 3
Completed
- Conditions
- Alzheimer DiseaseCognition Disorders
- First Posted Date
- 1999-11-01
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Novartis
- Registration Number
- NCT00000174
- Locations
- 🇺🇸
St. Louis University, St. Louis, Missouri, United States
🇺🇸Clinical Studies, Ltd., Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸St. Paul Medical Center, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath